Kiadis to present at the Jefferies 2020 Healthcare Conference

Amsterdam, The Netherlands, May 26, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces that Kiadis will participate in the 2020 Jefferies Virtual Healthcare Conference. Arthur Lahr, chief executive officer, will participate in a fireside chat on Wednesday, June 3, 2020 at 11:00am EDT.

The presentation will be webcast live and may be accessed by visiting the "For Investors" section of the Company's website under the "Events and Presentations" tab at https://www.kiadis.com/. A replay of the webcast will be available for 90 days.

Date: Wednesday, June 3, 2020
Time: 11:00am EDT
Webcast: http://wsw.com/webcast/jeff126/kds/

Kiadis Pharma Contacts:

Kiadis Pharma: Maryann Cimino, Sr. Manager, Corporate Affairs Tel. [phone] [e-mail]

Optimum Strategic Communications: Mary Clark, Supriya Mathur, Hollie Vile Tel: [phone] David Brilleslijper (Amsterdam) Tel: [phone] [e-mail]

Dutch Translation/Nederlandse vertaling

Kiadis presenteert op de Jefferies Healthcare Conference van 2020

Amsterdam, Nederland, 26 mei 2020 – Kiadis Pharma nv (‘Kiadis’) (Euronext Amsterdam en Brussel: KDS), een biofarmaceutische onderneming in de klinische fase, maakt vandaag bekend dat Kiadis zal deelnemen aan de Jefferies Virtual Healthcare Conference van 2020. Arthur Lahr, chief executive officer, zal op woensdag 3 juni 2020 om 11.00 uur EDT deelnemen aan een interview gesprek.

De presentatie wordt live uitgezonden en kan worden bekeken via het tabblad ‘For Investors’ door op het subtabblad ‘Events and Presentations’ te klikken op de website van de onderneming: https://www.kiadis.com/. Een herhaling van de webcast blijft 90 dagen beschikbaar.

Datum: woensdag 3 juni 2020
Tijdstip: 11.00 uur EDT
Webcast: http://wsw.com/webcast/jeff126/kds/

Dit persbericht vormt een vertaling van het gepubliceerde Engelstalige persbericht. Bij eventuele verschillen is de tekst van het Engelstalige persbericht altijd bepalend.

About Kiadis Pharma’s K-NK-Cell Therapies
Kiadis Pharma’s NK-cell programs consist of off-the-shelf and haploidentical donor cell therapy products for the treatment of liquid and solid tumors as adjunctive and stand-alone therapies.  

The Company’s NK-cell PM21 particle technology enables improved ex vivo expansion and activation of anti-cancer cytotoxic NK-cells supporting multiple high-dose infusions. Kiadis Pharma’s proprietary off-the-shelf NK-cell platform is based on NK-cells from unique universal donors. The Kiadis Pharma off-the-shelf K-NK platform can make NK-cell therapy product rapidly and economically available for a broad patient population across a potentially wide range of indications.